Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review

被引:193
作者
Lane, R [1 ]
Baldwin, D [1 ]
机构
[1] UNIV SOUTHAMPTON, SOUTHAMPTON, HANTS, ENGLAND
关键词
D O I
10.1097/00004714-199706000-00012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selective pharmacology of the selective serotonin reuptake inhibitors (SSRIs) results in a. lower potential for pharmacodynamic drug interactions relative to other antidepressants such as the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). However, the SSRIs have been implicated in the development of the serotonin syndrome-a potentially life-threatening complication of treatment with psychotropic drugs. The syndrome is produced most often by the concurrent use of two or more drugs that enhance central nervous system serotonin activity and often goes unrecognized because of the varied anti nonspecific nature of its clinical features. The serotonin syndrome is characterized by alterations in cognition (disorientation, confusion), behavior (agitation, restlessness), autonomic nervous system function (fever, shivering, diaphoresis, diarrhea), and neuromuscular (ataxia, hyperreflexia, myoclonus) activity. The difference between this syndrome and the occurrence of adverse effects caused by serotonin reuptake inhibitors alone is the clustering of the signs and symptoms, their severity, and their duration. There are important pharmacokinetic interactions between SSRIs and other serotonergic drugs due principally to their effects on the cytochrome P450(CYP) isoenzymes, the potential for which varies widely amongst the SSRI group, which may increase the Likelihood of a pharmacodynamic interaction. The exceptionally long washout period required after fluoxetine discontinuation may cause additional problems and/or inconvenience. Patients with serotonin syndrome usually respond to discontinuation of drug therapy and supportive care alone, but they may also require treatment with an antiserotonergic agent such as cyproheptadine, methysergide, and/or propranolol. To reduce the occurrence, morbidity, and mortality of the serotonin syndrome, it must be both prevented by prudent pharmacotherapy and given prompt recognition when it is present.
引用
收藏
页码:208 / 221
页数:14
相关论文
共 147 条
[61]  
HAWLEY CJ, 1995, J PSYCHOPHARMACOL S3, V9, P87
[62]  
HENDRICKX B, 1991, CURR THER RES CLIN E, V49, P106
[63]   TOXICITY AND DEATHS FROM 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) [J].
HENRY, JA ;
JEFFREYS, KJ ;
DAWLING, S .
LANCET, 1992, 340 (8816) :384-387
[64]   THE COMBINATION OF FLUOXETINE AND LITHIUM IN CLINICAL-PRACTICE [J].
HOPWOOD, SE ;
BOGLE, S ;
WILDGUST, HJ .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 (04) :325-327
[65]  
JACOBSEN FM, 1991, J CLIN PSYCHIAT, V52, P217
[66]   POTENTIAL FLUOXETINE SELEGILINE INTERACTION [J].
JERMAIN, DM ;
HUGHES, PL ;
FOLLENDER, AB .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (10) :1300-1300
[67]  
JOFFE RT, 1993, J CLIN PSYCHIAT, V54, P269
[68]  
JOFFE RT, 1994, J CLIN PSYCHIAT, V55, P24
[69]  
KAMEI J, 1992, RES COMMUN CHEM PATH, V76, P371
[70]   SERTRALINE INTOXICATION IN A CHILD [J].
KAMINSKI, CA ;
ROBBINS, MS ;
WEIBLEY, RE .
ANNALS OF EMERGENCY MEDICINE, 1994, 23 (06) :1371-1374